FDA Grants Breakthrough Therapy Status to Bezuclastinib in GIST
Waltham, Massachusetts & Boulder, Colorado, January 26, 2026 — Cogent Biosciences, Inc. announced that the U.S. Food and Drug...
tyrosine kinase inhibitor
Advertisement
Cogent NDA for Bezuclastinib Advances Under FDA RTOR
WALTHAM, Mass. & BOULDER, Colo., January 20, 2026 — Cogent Biosciences announced that the U.S. Food and Drug Administration...
Cogent Biosciences Secures $475M to Advance Precision Therapies
Dateline — WALTHAM, Mass. and BOULDER, Colo., November 11, 2025:Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company developing precision...
Advertisement
